多种菌株益生菌补充剂对2型糖尿病血糖控制的影响 - 随机对照试验
Venkata Chaithanya1, Janardanan Kumar2, Kakithakara Vajravelu Leela1
1Department of Microbiology, SRM Medical College Hospital and Research Centre, SRMIST, Kattankulathur, Chengalapattu 603203, Tamil Nadu, India.
Life (Basel, Switzerland)
|November 27, 2024
概括
多种菌株益生菌显著改善了2型糖尿病 (T2DM) 患者的血糖控制和高密度胆固醇. 这种饮食干预显示出良好的耐受性和管理T2DM代谢参数的潜力.
科学领域:
- 代谢健康 代谢健康
- 微生物组研究 微生物组研究
- 糖尿病管理 糖尿病管理
背景情况:
- 高血糖是2型糖尿病 (T2DM) 的标志,需要有效的管理策略.
- 包括益生菌在内的饮食干预措施正在探索,以补充传统T2DM疗法.
研究的目的:
- 评估多菌株益生菌补充剂对T2DM患者的血糖控制和脂质资料的影响.
- 在这个人群中评估益生菌补充剂的安全性和耐受性.
主要方法:
- 一项为期24周的随机对照试验与130名T2DM参与者进行.
- 参与者被分配到多种菌株益生菌或安慰剂组中.
- 关键结局包括禁食血糖 (FBG),食后血糖 (PPBG),糖化血红蛋白 (HbA1c) 和脂质配置文件,在基线和干预后测量.
主要成果:
- 益生菌组显示HbA1c显著降低 (p = 0.004) 和HDL-c显著增加 (p = 0.023).
- 在益生菌组中观察到总体脂质样本的改善.
- 观察到FBG和PPBG下降的趋势,没有报告严重的不良影响,表明良好的益生菌耐受性.
结论:
- 多菌株益生菌补充剂可能为T2DM患者的代谢参数带来好处.
- 益生菌显示出作为辅助饮食干预措施的潜力,以改善血糖控制和脂质配置文件.
- 进一步研究机制和优化配方是必要的,以加强糖尿病控制.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171


